Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials-Reference-Cited by-同舟云学术

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Published:2020-03-21 Issue:3 Volume:10 Page:431-447
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Leonardi Craig,Reich Kristian^ORCID,Foley Peter^ORCID,Torii Hideshi,Gerdes Sascha,Guenther Lyn^ORCID,Gooderham Melinda^ORCID,Ferris Laura K.^ORCID,Griffiths Christopher E. M.,ElMaraghy Hany,Crane Heidi,Patel Himanshu,Burge Russel,Gallo Gaia,Shrom David,Leung Ann,Lin Chen-Yen,Papp Kim^ORCID

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s13555-020-00367-x.pdf

Reference54 articles.

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.

2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581–8.

3. World Health Organization. WHO global report on psoriasis. Switzerland: WHO Press; 2016.

4. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031–42.

5. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199–205.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies;Expert Opinion on Drug Safety;2024-09-12

2. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials;Journal of the American Academy of Dermatology;2024-08

3. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis);Dermatology and Therapy;2024-05-15

4. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study;Drug Safety;2024-04-30

5. Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score;Clinical and Experimental Dermatology;2024-04-15